Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ. Meredith PA, et al. Among authors: olofsson b. J Am Coll Cardiol. 2008 Dec 9;52(24):2000-7. doi: 10.1016/j.jacc.2008.09.011. J Am Coll Cardiol. 2008. PMID: 19055992 Free article.
Albuminuria in chronic heart failure: prevalence and prognostic importance.
Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators and Committees. Jackson CE, et al. Among authors: olofsson b. Lancet. 2009 Aug 15;374(9689):543-50. doi: 10.1016/S0140-6736(09)61378-7. Lancet. 2009. PMID: 19683640
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. McMurray JJ, et al. Among authors: olofsson b. Lancet. 2003 Sep 6;362(9386):767-71. doi: 10.1016/S0140-6736(03)14283-3. Lancet. 2003. PMID: 13678869 Clinical Trial.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Granger CB, et al. Among authors: olofsson b. Lancet. 2003 Sep 6;362(9386):772-6. doi: 10.1016/S0140-6736(03)14284-5. Lancet. 2003. PMID: 13678870 Clinical Trial.
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Young JB, et al. Among authors: olofsson b. Circulation. 2004 Oct 26;110(17):2618-26. doi: 10.1161/01.CIR.0000146819.43235.A9. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492298 Clinical Trial.
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV; Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Yusuf S, et al. Among authors: olofsson b. Circulation. 2005 Jul 5;112(1):48-53. doi: 10.1161/CIRCULATIONAHA.104.528166. Epub 2005 Jun 27. Circulation. 2005. PMID: 15983242 Clinical Trial.
342 results